A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients
Authors:
- Lawrence E GibsonLGLawrence E Gibson
- 1 January 1995
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 32 (1) , 114-116
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- 6-Thioguanine treatment of psoriasis: Experience in 81 patientsJournal of the American Academy of Dermatology, 1994
- Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipientThe Lancet, 1993
- Human liver thiopurine methyltransferase pharmacogeneticsPharmacogenetics, 1992
- THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS1Transplantation, 1992
- Azathioprine in dermatologyJournal of the American Academy of Dermatology, 1991
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990
- Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphismClinical Pharmacology & Therapeutics, 1989
- Childhood leukaemia: a relationship between intracellular 6‐ mercaptopurine metabolites and neutropenia.British Journal of Clinical Pharmacology, 1983
- AzathioprineInternational Journal of Dermatology, 1981
- Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical propertiesClinica Chimica Acta, 1978